Literature DB >> 20485375

Recurrent IDH mutations in high-risk myelodysplastic syndrome or acute myeloid leukemia with isolated del(5q).

A Pardanani, M M Patnaik, T L Lasho, M Mai, R A Knudson, C Finke, R P Ketterling, R F McClure, A Tefferi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20485375     DOI： 10.1038/leu.2010.98

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   12.883


× No keyword cloud information.
  15 in total

1.  Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes.

Authors:  Marta Fernandez-Mercado; Adam Burns; Andrea Pellagatti; Aristoteles Giagounidis; Ulrich Germing; Xabier Agirre; Felipe Prosper; Carlo Aul; Sally Killick; James S Wainscoat; Anna Schuh; Jacqueline Boultwood
Journal:  Haematologica       Date:  2013-07-05       Impact factor: 9.941

2.  Clinical effect of point mutations in myelodysplastic syndromes.

Authors:  Rafael Bejar; Kristen Stevenson; Omar Abdel-Wahab; Naomi Galili; Björn Nilsson; Guillermo Garcia-Manero; Hagop Kantarjian; Azra Raza; Ross L Levine; Donna Neuberg; Benjamin L Ebert
Journal:  N Engl J Med       Date:  2011-06-30       Impact factor: 91.245

Review 3.  Mutations in epigenetic regulators in myelodysplastic syndromes.

Authors:  Gorica Nikoloski; Bert A van der Reijden; Joop H Jansen
Journal:  Int J Hematol       Date:  2012-01-11       Impact factor: 2.490

Review 4.  The need for additional genetic markers for myelodysplastic syndrome stratification: what does the future hold for prognostication?

Authors:  Zaher K Otrock; Ramon V Tiu; Jaroslaw P Maciejewski; Mikkael A Sekeres
Journal:  Expert Rev Hematol       Date:  2013-02       Impact factor: 2.929

5.  Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin.

Authors:  Farhad Ravandi; Keyur Patel; Rajyalakshmi Luthra; Stefan Faderl; Marina Konopleva; Tapan Kadia; Mark Brandt; Sherry Pierce; Steven Kornblau; Michael Andreeff; Xuemei Wang; Guillermo Garcia-Manero; Jorge Cortes; Hagop Kantarjian
Journal:  Cancer       Date:  2011-10-21       Impact factor: 6.921

6.  Rare mutations in DNMT3A in myeloproliferative neoplasms and myelodysplastic syndromes.

Authors:  M Brecqueville; N Cervera; V Gelsi-Boyer; A Murati; J Adélaïde; M Chaffanet; J Rey; N Vey; M J Mozziconacci; D Birnbaum
Journal:  Blood Cancer J       Date:  2011-05-13       Impact factor: 11.037

7.  Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.

Authors:  Sadudee Chotirat; Wanna Thongnoppakhun; Orathai Promsuwicha; Chetsada Boonthimat; Chirayu U Auewarakul
Journal:  J Hematol Oncol       Date:  2012-03-07       Impact factor: 23.168

8.  IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F.

Authors:  A Tefferi; T Jimma; N H Sulai; T L Lasho; C M Finke; R A Knudson; R F McClure; A Pardanani
Journal:  Leukemia       Date:  2011-09-13       Impact factor: 11.528

9.  A nonsense mutation of IDH1 in myelodysplastic syndromes and related disorders.

Authors:  K Yoshida; M Sanada; M Kato; R Kawahata; A Matsubara; J Takita; L-Y Shih; H Mori; H P Koeffler; S Ogawa
Journal:  Leukemia       Date:  2010-10-21       Impact factor: 12.883

10.  Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium.

Authors:  A Tefferi; O Abdel-Wahab; F Cervantes; J D Crispino; G Finazzi; F Girodon; H Gisslinger; J Gotlib; J-J Kiladjian; R L Levine; J D Licht; A Mullally; O Odenike; A Pardanani; R T Silver; E Solary; T Mughal
Journal:  Blood Cancer J       Date:  2011-03-04       Impact factor: 11.037
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.